Drug
Amibegron clinical trials
Also written SR58611A.
- studies test it
- 14
- open now
- 0
- in phase 3
- 14
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
- SR58611A
- 10
Studies by the year they started
14 studies that test it; most in 2005 (5)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses amibegron is read from its arms, and is right about nine times in ten.
Testing it · 14
- Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive DisorderCompletedPhase 3SanofiNCT00855530Written as amibegron (SR58611A)
- Efficacy and Safety of SR58611 Compared to Placebo and ParoxetineCompletedPhase 3SanofiNCT00825058Written as amibegron (SR58611A)
- Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and ParoxetineCompletedPhase 3SanofiNCT00825019Written as amibegron (SR58611A)
- Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive DisorderCompletedPhase 3SanofiNCT00432614Written as SR58611A
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)CompletedPhase 3SanofiNCT00385307Written as amibegron (SR58611A)
- Efficacy and Safety of SR58611A in Patients With Major Depressive DisorderCompletedPhase 3SanofiNCT00252330Written as SR58611A
- Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety DisorderCompletedPhase 3SanofiNCT00252343Written as SR58611A
- An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With DepressionCompletedPhase 3SanofiNCT00319709Written as SR58611A
- Efficacy and Safety of SR58611A in Patients With Major Depressive DisorderCompletedPhase 3SanofiNCT00252356Written as SR58611A
- An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety DisorderCompletedPhase 3SanofiNCT00266747Written as SR58611A
- A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive DisorderCompletedPhase 3SanofiNCT00345098Written as SR58611A
- An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety DisorderTerminatedPhase 3SanofiNCT00535340Written as SR58611A
- Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety DisorderTerminatedPhase 3SanofiNCT00397098Written as SR58611A
- An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety DisorderCompletedPhase 3SanofiNCT00332891Written as SR58611A
Codes
What other systems call amibegron · ClinicalTrials.gg INT003653
- MeSH (NLM) C076252amibegronConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PDQ3ME68U3AMIBEGRONConfirmed FDA, NLM, Wikidata
- Wikidata Q4746121amibegronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77932AmibegronOne source FDA
- DrugBank DB05395One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C076252 | amibegron | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PDQ3ME68U3 | AMIBEGRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4746121 | amibegron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77932 | Amibegron | One source FDA |
| DrugBank | DB05395 | — | One source Wikidata |
Also registered as amibegron hydrochloride (UNII N910CJ679E).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.